

AMENDMENTS TO THE CLAIMS

Claims 1-3 (canceled).

Claim 4 (original): A kit for genotyping human multidrug resistance gene (*MDR1*) single nucleotide polymorphism C3435T, comprising primers having the sequences of SEQ ID NOs: 1-3.

Claims 5-16 (canceled).

Claim 17 (original): An isolated DNA molecule useful as a primer for genotyping human multidrug resistance gene (*MDR1*) single nucleotide polymorphism C3435T, said DNA is selected from the group consisting of SEQ ID NOs: 1-3.

Claims 18-20 (canceled).

Claim 21 (new): A method of genotyping human multidrug resistance gene (*MDR1*) single nucleotide polymorphism C3435T, comprising the steps of:

preparing DNA samples from an individual;

amplifying said DNA with primer pairs comprising of a wild type-specific primer or a mutant-specific primer and a common reverse primer of claim 17; and

identifying the products of said DNA amplification, wherein the presence of products amplified by said mutant-specific primer and said reverse primer indicate said individual has the genotype C3435T.

Claim 22 (new): The method of claim 21, wherein said products of DNA amplification are identified by a method selected from the group consisting of real-time fluorescence-based analysis, melt curve analysis and gel electrophoresis.

Claim 23 (new): The method of claim 22, wherein said gel electrophoresis identifies a product of 134 base pairs that correspond to genotype C3435T.